Day: September 12, 2023

Takeout tips are down, but guests are dining out more often than last year—and rewarding great service when they doLightspeed Commerce Inc.New Lightspeed Data Shows Guests Are Tipping More When Dining OutMONTREAL, Sept. 12, 2023 (GLOBE NEWSWIRE) — Lightspeed Commerce Inc. (NYSE | TSX: LSPD) released new hospitality industry data showing that tipping is on the rise when consumers dine out, with the highest tips occurring at bars and fine dining restaurants. On the other hand, average takeout and delivery tips dropped to around 8%, suggesting consumers might be pulling back on tips outside of traditional service venues. The data is based on a sample of thousands of restaurants powered by Lightspeed across North America. Powering the world’s best businesses, Lightspeed is the unified POS and payments platform for ambitious...

American Rebel Holdings, Inc.https://youtu.be/Xdc5ay63ydENashville, TN, Sept. 12, 2023 (GLOBE NEWSWIRE) — American Rebel Holdings, Inc. – America’s Patriotic Brand (NASDAQ: AREB; AREBW), a designer, manufacturer and marketer of branded safes and personal security and self-defense products, today announced that it has received very positive feedback from CEO Andy Ross’ appearance on Fox & Friends (https://www.foxnews.com/category/shows/fox-friends-weekend) Saturday, September 9. The discussion centered around the recent publicity and issues surrounding the Liberty Safe breach and the American Rebel/Champion Safe policy governing customer privacy. To watch the segment, click on the link below: In the interview, Andy Ross explains the trust his customers put in American Rebel, Champion Safe and Superior Safe to protect...

JERUSALEM, Sept. 12, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX, “Entera”) and OPKO Biologics, Inc., a subsidiary of OPKO Health, Inc. (NASDAQ: OPK, “OPKO”) have entered into a Research Collaboration Agreement. Under the terms of the Agreement, OPKO will supply its proprietary long-acting GLP-2 peptide and certain Oxyntomodulin (OXM) analogs for the development of oral tablet formulations using Entera’s proprietary oral delivery technology. It is challenging to administer peptides orally due to their rapid degradation in the gastrointestinal tract and negligible permeability. Treatment with Glucagon-Like Peptide-2 (GLP-2) analogs has been shown to improve the absorption of nutrients in patients with short bowel syndrome (SBS) and reduce parenteral support requirements. Teduglutide, the only approved GLP-2 analog, requires...

The company’s new technology offering brings much-needed cross-chain security, liquidity to the industry ZURICH, September 12, 2023 – 21.co today announced the launch of 21.co Wrapped Tokens. The Company’s first wrapped tokens feature a mix of underlyings from the top crypto assets by market capitalization, across multiple blockchain networks. Wrapped tokens present the opportunity to increase cross-chain liquidity and utility regardless of blockchain ecosystem, and address the security challenges of cross-chain bridging. 21.co is uniquely positioned to deliver institutional grade security and liquidity at scale through the suite, bolstered by Onyx, 21.co’s proprietary product management system, which has created and redeemed over $3.3B in crypto-backed assets. Effective cross-chain interoperability and liquidity allow members of the...

Portal provides resources to raise awareness around mental health and suicide prevention MALVERN, Pa., Sept. 12, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, in recognition of National Suicide Prevention Awareness Month, announced the launch of the NeuroStar Voices Portal, a platform aimed at fostering connections, sharing stories of possibility, and building a supportive community for individuals battling depression. To illustrate the types of experiences people may share through the portal, Neuronetics is highlighting Damon Devine, a NeuroStar patient who broke the cycle of multiple suicides among the men in his family. “Depression can be isolating,...

Investigational New Drug (IND) submission to FDA on target for Q1 2024 SPC-15, is a novel Serotonin 4 receptor agonist against stress, developed in conjunction with Columbia University ENGLEWOOD CLIFFS, NJ, Sept. 12, 2023 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced the initiation of an exploratory feasibility study evaluating a selected delivery mechanism for its intranasal therapeutic drug SPC-15. The Company’s collaboration partner for the study is a developer and manufacturer of innovative drug delivery systems and technology. Eric Weisblum, Chief Executive Officer of Silo Pharma, stated, “We believe our research partner’s patented proprietary nasal-to-brain technology...

AUSTIN, Texas, Sept. 12, 2023 (GLOBE NEWSWIRE) — Lottery.com, Inc. (NASDAQ: LTRY, LTRYW) (“Lottery.com” or the “Company”) announced today that on September 8, 2023, it received formal notice (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has evidenced compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”) and the filing requirement Listing Rule 5250(c) (the “Periodic Filing Rule”). As announced on August 24, 2022, the company was notified that its ordinary shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Minimum Bid Price Requirement....

Aspo PlcPress releaseSeptember 12, 2023, at 3:45 p.m. Aspo’s subsidiary Leipurin signs a sale and lease back agreement for its property in Lithuania Aspo’s subsidiary Leipurin has signed a sale and lease back agreement for its office- and warehouse property in Kaunas, Lithuania. The buyer is an entrepreneur operating in the same industrial area in Kaunas. With this transaction and the signed lease agreement, Leipurin will continue its operations in Lithuania in the same premises. This transaction enables Leipurin’s goal to find more suitable premises in Lithuania. The sale price of the property is EUR 1.1 million and the resulting sales gain is EUR 0.8 million. The agreed leaseback period is up to 24 months and the annual rent will be EUR 132 thousand. “Leipurin’s Lithuanian real estate transaction is a continuation of Leipurin’s...